[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356789-105":59,"doc-detail-356789-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","transcriptomic-deconvolution-reveals-prognostic-immune-signatures-and-immunotherapy-responsive-subtypes-in-male-breast-cancer","Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer","","Male breast cancer is a rare malignancy with biological and clinical distinctions from female breast cancer, and limited sex-specific immune biomarker data has constrained male inclusion in immunotherapy trials. Transcriptomic profiling of 123 male breast cancers quantified PD-1/PD-L1, immune scores, and immune-cell infiltration via deconvolution tools. TIDE was used to estimate immune checkpoint inhibitor response. A distinct high-PD-L1/high-immune-score subset showed enriched infiltrating immune populations and two transcriptional molecular subgroups, with immune patterns varying by germline mutations, subtype, grade, androgen receptor, and Ki-67.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/transcriptomic-deconvolution-reveals-prognostic-immune-signatures-and-immunotherapy-responsive-subtypes-in-male-breast-cancer/356789/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/transcriptomic-deconvolution-reveals-prognostic-immune-signatures-and-immunotherapy-responsive-subtypes-in-male-breast-cancer/356789.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is sex-specific immune biomarker data important for male breast cancer immunotherapy?","Question",{"text":113,"@type":114},"Male breast cancer has distinct biological and clinical features, but immune biomarkers are not sex-specific, limiting male participation in immunotherapy trials.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were immune signatures and immunotherapy-responsive subtypes analyzed?",{"text":118,"@type":114},"The study profiled transcriptomes of 123 male breast cancers, assessed PD-1/PD-L1, immune scores, and immune-cell infiltration using deconvolution tools, and applied the TIDE algorithm to predict response to checkpoint inhibitors.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the results show about responders and immune cell composition?",{"text":122,"@type":114},"A subset with high PD-L1 expression and high immune scores was predicted to respond to immunotherapy, and immune deconvolution highlighted abundant CD4+ memory resting T cells and macrophage populations. Two transcriptionally distinct molecular subgroups were identified, with one enriched for immune-related pathways and predicted responders.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356789,1790533406,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Silvestri et al. Breast Cancer Research (2026) 28:90 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02236-5](https://doi.org/10.1186/s13058-026-02236-5)  \nRESEARCH Open Access  \nTranscriptomic deconvolution reveals  \nprognostic immune signaturesand immunotherapy-responsive subtypes in male breast cancer  \nValentina Silvestri1, Virginia Valentini1, Agostino Bucalo1, Virginia Porzio 1, Giorgia Scafetta2, Bruna Cerbelli3, Ines Zanna4, Simonetta Bianchi5, Maria Grazia Tibiletti6, Ileana Carnevali7, Daniele Calistri8, Valentina Arcangeli8, Valentina Zampiga8, Elisa Gasparini9, Laura Cortesi9,10, Giuseppe Giannini1, Carlo Capalbo11,12, Stephen B. Fox 13,14, Giovanna Masala15, Silvia Mezi3, Giulia d’Amati3 and Laura Ottini1*  \nAbstract  \nBackground Male breast cancer (MBC) is a rare malignancy with distinct biological and clinical features compared to its female counterpart. Emerging evidence suggests that a subset of MBCs may exhibit an immunogenic tumor microenvironment; however, the lack of sex-specific data on immune biomarkers has limited the inclusion of male patients in immunotherapy trials.  \nMethods We performed transcriptomic profiling of 123 MBCs, including 41 with germline pathogenic variants (PVs) in BRCA2 (n = 26), BRCA1 (n = 12), and PALB2 (n = 3) . Immune characterization included PD-1 and PD-L1 expression, immune scores, and immune cell infiltration using deconvolution tools. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was applied to predict potential response to immune checkpoint inhibitors.  \nResults A distinct subset of MBCs showed high PD-L1 expression and high immune scores. Immune deconvolution revealed that CD4 + memory resting T cells (24 . 5%), M2 macrophages (14 .4%), and M0 macrophages (13 . 8%) were the most abundant infiltrating immune populations within the tumor microenvironment. Notably, 37.4% of tumors were predicted to respond to immunotherapy, primarily within the Luminal B subtype. These tumors demonstrated significantly higher PD-1/PD-L1 expression, higher immune scores, and enriched immune cell infiltration, compared to non-responders. Unsupervised clustering identified two transcriptionally distinct molecular subgroups. Cluster 1 was enriched for immune-related pathways and comprised the majority of predicted responders. Immune infiltration patterns varied significantly according to germline mutation status, intrinsic subtype, histological grade, androgen receptor expression, and Ki-67 proliferation index.  \n*Correspondence:  \nLaura Ottini [laura.ottini@uniroma1.it](laura.ottini@uniroma1.it)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nSilvestri et al. Breast Cancer Research (2026) 28:90 Page 2 of 15  \nConclusions This study identifies a transcriptionally defined, immunogenic subset of MBCs with potential sensit","cbCaioAXsSGdZY9O","https://ap.wps.com/l/cbCaioAXsSGdZY9O","pdf",1555931,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is sex-specific immune biomarker data important for male breast cancer immunotherapy?\",\"answer\":\"Male breast cancer has distinct biological and clinical features, but immune biomarkers are not sex-specific, limiting male participation in immunotherapy trials.\"},{\"question\":\"How were immune signatures and immunotherapy-responsive subtypes analyzed?\",\"answer\":\"The study profiled transcriptomes of 123 male breast cancers, assessed PD-1/PD-L1, immune scores, and immune-cell infiltration using deconvolution tools, and applied the TIDE algorithm to predict response to checkpoint inhibitors.\"},{\"question\":\"What did the results show about responders and immune cell composition?\",\"answer\":\"A subset with high PD-L1 expression and high immune scores was predicted to respond to immunotherapy, and immune deconvolution highlighted abundant CD4+ memory resting T cells and macrophage populations. Two transcriptionally distinct molecular subgroups were identified, with one enriched for immune-related pathways and predicted responders.\"}]","Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer | PDF",1790127304,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea2decb4461df30997b3077730c5c142.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a2883f70b159cdc8781b87317553e8f.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39833137a2102d28b6325214f28548cb.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57e59d128c150932df21ac195dc91fb5.webp",980,1306]